Next Article in Journal
Expression of the Grape VaSTS19 Gene in Arabidopsis Improves Resistance to Powdery Mildew and Botrytis cinerea but Increases Susceptibility to Pseudomonas syringe pv Tomato DC3000
Previous Article in Journal
Juvenile Moyamoya and Craniosynostosis in a Child with Deletion 1p32p31: Expanding the Clinical Spectrum of 1p32p31 Deletion Syndrome and a Review of the Literature
Article

Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma

by 1,*,†, 1,†, 1, 1, 1 and 2,*
1
Department of Biochemistry & Molecular Biology, College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
2
Division of Hematology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2017, 18(9), 1999; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18091999
Received: 22 August 2017 / Revised: 11 September 2017 / Accepted: 13 September 2017 / Published: 17 September 2017
(This article belongs to the Section Biochemistry)
Immunomodulatory drugs (IMiDs) are profoundly active compounds in the treatment of patients with multiple myeloma (MM). However, despite the fact that treatment with IMiDs has dramatically improved survival for patients with MM, the majority of MM patients develop IMiDs resistance over time. We have found that expression of functional cereblon is required for IMiDs′ action. In addition, it has been reported that cells expressing high levels of cereblon are resistant to proteasome inhibitor, implying that patients with high levels of cereblon should be resistant to proteasome inhibitor. If the above conclusions are correct, cereblon could be considered as a biomarker to determine which standard regimens should be used to treat patients with MM. Unfortunately, the conclusions mentioned above have not been clinically confirmed. In order to confirm these conclusions, we have generated three highly specific mouse monoclonal antibodies (mAbs) against full-length human cereblon. These mAbs can be used to do western blot, immunoprecipitation and immunohistochemistry staining. In addition, their epitopes have been precisely determined and the peptides covering their epitopes completely blocked the antibody binding to cereblon in western blot analysis or in immunohistochemistry staining of MM patients′ specimens. View Full-Text
Keywords: multiple myeloma (MM); cereblon (CRBN); monoclonal antibody (mAb); epitope; immunohistochemistry (IHC) staining; immunoprecipitation; immunomodulatory drugs (IMiDs) multiple myeloma (MM); cereblon (CRBN); monoclonal antibody (mAb); epitope; immunohistochemistry (IHC) staining; immunoprecipitation; immunomodulatory drugs (IMiDs)
Show Figures

Figure 1

MDPI and ACS Style

Chang, X.; Xu, Q.; Hou, Y.; Li, C.; Xu, Y.; Stewart, A.K. Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma. Int. J. Mol. Sci. 2017, 18, 1999. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18091999

AMA Style

Chang X, Xu Q, Hou Y, Li C, Xu Y, Stewart AK. Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma. International Journal of Molecular Sciences. 2017; 18(9):1999. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18091999

Chicago/Turabian Style

Chang, Xiubao, Qinqin Xu, Yuexian Hou, Cynthia Li, Ye Xu, and A. K. Stewart 2017. "Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma" International Journal of Molecular Sciences 18, no. 9: 1999. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18091999

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop